Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Primary biliary cholangitis (PBC) Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Primary biliary cholangitis (PBC) Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Primary biliary cholangitis (PBC) Disease Pipeline Drugs Assessment

 

Overview:

Primary Biliary Cholangitis is a chronic, presumable autoimmune liver diseases which further leads to progressive cholestasis and often end-stage liver diseases. This disease was formerly called as Primary Biliary Cirrhosis. PBC is the most common disease of women. Symptoms of PBC includes fatigue, pruritus, right upper quadrant discomfort, hepatomegaly, hyperpigmentation, jaundice, splenomegaly, xerophthalmia, kayser-fleischer rings etc.

Generally 25% of patients with PBC can be diagnosed by routine blood evaluation. Diagnosis of PBC includes evaluation of levels of ceruloplasmin, bile acids, serum hyaluronate, determination of presence of antimitochondrial antibodies (AMAs) in serum by ELISA and Complement Fixation Test. Imaging studies of PBC is done by Ultrasonography, CT Scan or MRI.

Ursodeoxycholic acid (UDCA) is the main treatment for people with PBC and Obeticholic acid (OCA) is a new treatment that works by improving bile flow and reducing inflammation. Medications like antibiotics can be given to treat other symptoms of PBC like pruritis. If the liver is completely damaged then Liver transplantation is recommended.

 

Segmentation:

By Trial Phase, Primary Biliary Cholangitis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Primary Biliary Cholangitis pipeline drugs are segmented as:

  • Novartis Pharmaceuticals
  • Janssen Research & Development, LLC
  • CymaBay Therapeutics, Inc.
  • Zydus Discovery DMCC
  • GlaxoSmithKline
  • Pfizer
  • Genfit
  • Gilead Sciences

By Molecule, Primary Biliary Cholangitis pipeline drugs are segmented as:

  • Ursodeoxycholic acid
  • Obeticholic acid
  • Elafibranor
  • Seladelpar
  • Saroglitazar magnesium
  • Abataceopt
  • Rituximab
  • Others

By Route of Administration, Primary Biliary Cholangitis pipeline drugs are segmented as:

  • Oral
  • Parenteral

 

Space Analysis:

  • In October 2017, NGM biopharmaceuticals initiated phase II expansion trial for Non-Alcoholic Steatohepatitis. It has completed the Phase 2a proof-of-concept trial for 28 days in patients with primary biliary cholangitis, in which the results demonstrated that there is a significant reduction of ALP (Biochemical market of liver health) along with no significant worsening of pruritus with 28 days treatment of NGM282.
  • In October 2017, Gilead Sciences completed Phase 2 studies of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH) , the results determines that the higher dose of GS-0976 (20 mg taken orally once daily) when administered for 12 weeks was associated with statistically significant reductions in hepatic steatosis (buildup of fat in the liver) and a noninvasive marker of fibrosis (TIMP-1)

 

Report Description:

Primary Biliary Cholangitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Primary Biliary Cholangitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Primary Biliary Cholangitis disease pipeline drugs development. This report studies the dynamics of the Primary Biliary Cholangitis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Primary Biliary Cholangitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases

 

 

  • AbbVie Inc. (U.S.)
  • ObsEva (Switzerland)
  • Bayer AG (Germany)
  • Repros Therapeutics Inc. (U.S.)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553